WO2018015776A1 - Composition basée sur l'action synergique de l'acide lipoïque et de la sélénite et son utilisation pour la prévention et le traitement de troubles néoplasiques - Google Patents

Composition basée sur l'action synergique de l'acide lipoïque et de la sélénite et son utilisation pour la prévention et le traitement de troubles néoplasiques Download PDF

Info

Publication number
WO2018015776A1
WO2018015776A1 PCT/HU2017/050013 HU2017050013W WO2018015776A1 WO 2018015776 A1 WO2018015776 A1 WO 2018015776A1 HU 2017050013 W HU2017050013 W HU 2017050013W WO 2018015776 A1 WO2018015776 A1 WO 2018015776A1
Authority
WO
WIPO (PCT)
Prior art keywords
selenite
sodium
acid
lipoic acid
alpha
Prior art date
Application number
PCT/HU2017/050013
Other languages
English (en)
Inventor
Gyula KULCSÁR
László LEX
Tamás CZÖMPÖLY
Original Assignee
Culex Patent Kft.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Culex Patent Kft. filed Critical Culex Patent Kft.
Publication of WO2018015776A1 publication Critical patent/WO2018015776A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • composition based on the synergistic action of lipoic acid and selenite and use thereof for the prevention and treatment of neoplastic disorders
  • the subject matter of the invention is a composition containing lipoic acid and selenite and a mixture of certain small molecules, applied for the prevention and treatment of neoplastic disorders.
  • Alpha-lipoic acid is an endogenous, disulfide bridge-containing short chain fatty acid.
  • the basic biological function of alpha-lipoic acid is that it is the cofactor of certain mitochondrial multi-enzyme complexes such as the pyruvate-dehydrogenase enzyme complex through which it has an important role in the decarboxylation of alpha-ketoacids and thus in the mitochondrial energy production.
  • the alpha-lipoic acid contains one chiral carbon atom, of its stereoisomers the R-enantiomer is the biologically active form as a cofactor of the above mentioned enzyme complex.
  • the alpha-lipoic acid is a strong antioxidant [1] and utilizing this property it is applied as a pharmaceutical in the treatment of diabetic neuropathy.
  • Both the alpha-lipoic acid and its reduced form the dihydrolipoic acid have been shown to be able to capture reactive oxygen species (e.g. hydroxyl radicals, superoxide radicals, hypochlorous acid) and to form complexes with the ions of various transition metals [2-4]. It has been shown that the alpha-lipoic acid is able to increase the level of reduced glutathione which is an important intracellular antioxidant molecule [5].
  • alpha-lipoic acid causes cell death in various cancer cell lines (Jurkat, H460, MCF-7 etc.) [6-10].
  • treatment with alpha-lipoic acid increases the production of superoxide anions in the mitrochondria, decreases the amount of anti-apoptotic proteins (bcl-2, bcl-xl), induces cytochrome c release from the mitochondria, activates caspase-9 and PARP-1, cumulatively induces the activation of the mitochondrial pathway of apoptosis in cancer cells [6, 7, 11].
  • caspase-independent cell death and autophagy also may have a role in the anti-cancer effect of alpha-lipoic acid [12, 13].
  • the treatment with alpha-lipoic acid is also capable to inhibit the PBK-Akt-mTOR cascade which is an important oncogenic signaling pathway.
  • Treatment with alpha-lipoic acid reduces both the total amount of Akt protein and the level of phosphorylated Akt [14].
  • the alpha-lipoic acid has been shown to increase the anti-tumor effect of certain cytostatics (5-fluorouracil, etoposide) [12, 15].
  • Selenium is an essential trace element, with the main biological function of being incorporated into selenoproteins and through the oxidoreductase activity of such proteins it contributes to the maintenance of the proper redox state of the cell [21]. On the basis of this selenium can be considered as an indirect antioxidant.
  • Selenium is present in foodstuffs in the form of different organic compounds: selenomethionine (SeMet), selenocysteine (SeCys), seleno-methyl-selenocysteine (SMSC); while in the soil it occurs mainly in the form of selenate and selenite.
  • the above mentioned compounds can be considered as redox-active, since in the presence of reduced glutathione, on the one hand as substrates of oxidoreductase enzymes they can be transformed to hydrogen selenide, accompanied by the production of reactive oxygen species, on the other hand selenide anions can be produced through a redox-cycle, also accompanied by the production of reactive oxygen species [22-24]. Numerous redox-active organic and inorganic selenium compounds have been shown to possess some degree of antitumor activity [25].
  • selenite anion of selenous acid
  • Selenite has been shown to influence numerous signal transduction pathways which have vital importance for cancer cells: in addition to the production of reactive oxygen species mentioned above, selenite is able to induce apoptosis through the inhibition of the Akt pathway, it is able to shift autophagy toward apoptosis through the inhibition of the Nfkappab pathway, additionally it can also induce caspase-independent cell death (necroptosis) [26-28].
  • Selenite has been shown to increase the in vivo effect of cisplatin in the A2780 tumor model [29].
  • alpha-lipoic acid and sodium-sulfite have not resulted in a synergistic increase of antitumor activity (see example 11), thus excluding the possibility that a redox reaction between alpha-lipoic acid and the selenite anion taking place in the cell culture media would account for the synergism of alpha-lipoic acid and sodium-selenite.
  • dihydrolipoic acid is formed intracellularly in the human body from alpha-lipoic acid, it is not a stable compound (it is easily oxidized), therefore its application in a composition according to the invention is not expedient.
  • alpha-lipoic acid and sodium-selenite can be further increased in a synergistic manner by the individual combination of the following active substances with a mixture of alpha-lipoic acid and sodium-selenite: L-tryptophan, D-tryptophan, L-methionine, D-phenylalanine, agmatine, phenylpyruvic acid, gentisic acid, pyrrole-2-carboxylic acid (see examples 18-25).
  • chemotherapeutic substances e.g. docetaxel, doxorubicin, taxane-derivatives, cisplatin etc.
  • docetaxel, doxorubicin, taxane-derivatives, cisplatin etc. which in general have serious toxicity, during a chemotherapeutic treatment became achievable with our invention.
  • the invention relates to therapeutical compositions for the prevention and treatment of neoplastic disorders and uses thereof.
  • the subject matter of the invention is a synergistic composition containing exclusively lipoic acid or a therapeutically acceptable salt thereof and selenite as the primary active substances, optionally in conjunction with one or more secondary active substance(s) with a maximal molecular weight of 280 daltons, and optionally in conjunction with one or more usual therapeutically acceptable carrier(s), diluent(s) and/or other excipient(s).
  • the composition contains exclusively the above mentioned primary active substances.
  • the composition in addition to the two primary active substances, comprises exclusively one or more secondary active substance(s) mentioned in points 4 and 5 below.
  • the composition may also comprise one or more usual pharmaceutical excipient(s) without a therapeutic effect (e.g. usual therapeutically acceptable carriers, diluents and/or other excipients).
  • synergistic composition comprising one or more compound(s) as secondary active substance(s) selected form the following group: L- tryptophan, D-tryptophan, L-methionine, D-phenylalanine, agmatine, phenylpyruvic acid, gentisic acid, pyrrole-2-carboxylic acid, L-arginine, D-arginine, L-phenylalanine, L-histidine, L-tyrosine, pyridoxine, D(+)-biotin, L(+)-ascorbic acid, L(-)-malic acid, D-(+)-glucosamine, ketoisocaproic acid (4-methyl-2-oxovaleric acid), cinnamic acid, adenosine, melatonin, p- coumaric acid and therapeutically acceptable salts thereof.
  • synergistic composition according to point 4 comprising one or more compound(s) as secondary active substance(s) selected form the following group: L- tryptophan, D-tryptophan, L-methionine, D-phenylalanine, agmatine, phenylpyruvic acid, gentisic acid, pyrrole-2-carboxylic acid and therapeutically acceptable salts thereof.
  • synergistic composition according to any of points 1-5 for use in the prevention or treatment of neoplastic disorders in mammals, particularly in humans.
  • a method for the prevention or treatment of neoplastic disorders characterized by that the patient in need of treatment is administered a synergistic composition according to any of points 1-5 in a therapeutically effective amount, preferably in an amount of 5-500 mg per kg body weight in 1-15 portion(s) per day.
  • Figure 1 dose-antitumor effect curves obtained on HELA cells with ( ⁇ )- alpha-lipoic acid applied in 0.5 mM, 0.4 mM, 0.3 mM concentrations, with sodium-selenite applied in 1 ⁇ , 0.75 ⁇ , 0.5 ⁇ concentrations, and with the combined application of the two compounds in the above concentrations.
  • Figure 1. part “B” plot of the antitumor effect on a normalized isobologram [34] obtained on HELA cells with the combined application of ( ⁇ )-alpha-lipoic (LA) acid and sodium-selenite (SEL) in the indicated concentrations.
  • LA normalized isobologram
  • Figure 2. part “A” dose-antitumor effect curves obtained on HELA cells with ( ⁇ )- alpha-lipoic acid applied in 0.5 mM, 0.4 mM, 0.3 mM concentrations, with sodium-selenite applied in 4 ⁇ , 3 ⁇ , 2 ⁇ concentrations, and with the combined application of the two compounds in the above concentrations.
  • Figure 1. part “B” plot of the antitumor effect on a normalized isobologram obtained on HELA cells with the combined application of ( ⁇ )-alpha- lipoic (LA) acid and sodium-selenite (SEL) in the indicated concentrations.
  • Figure 3 in vivo antitumor effect obtained on the C26 tumor model with ( ⁇ )-alpha- lipoic acid (LA) applied per se in a dose of 50mg/kg, with sodium-selenite applied per se in a dose of 1.5 mg/kg, and with the combined application of the two compounds in the above doses (LA+SEL).
  • Part "A” tumor volumes measured during the treatment period (*p ⁇ 0,001 vs. CTRL, vs. LA, vs. SEL).
  • Part “B” tumor weights measured on the 10 th day of the treatment (*p ⁇ 0,05 vs. CTRL, vs. LS; #p ⁇ 0,001 vs. SEL).
  • lipoic acid designates racemic lipoic acid [( ⁇ )-alpha-lipoic acid, which represents a preferred embodiment], and in addition enantiomers thereof [(+)-alpha-lipoic acid and (-)-alpha-lipoic acid], or any mixtures thereof.
  • the lipoic acid can be applied in the form of a salt, consequent from the intended use obviously in the form of a therapeutically acceptable salt.
  • the cation present in the salt can be derived from an organic or inorganic acid.
  • Preferred examples are salts formed with alkali metal and alkaline earth metal cations, or with a quaternary ammonium cation (or with other quaternary nitrogen-containing cation).
  • alkali metal and alkaline earth metal salts more preferred is the sodium salt.
  • the term "selenite” used alone designates a salt derived from selenous acid (thus in this general name we refer to the salt, for the sake of simplicity, with the name of the anion present in it).
  • the cation can be an alkali metal and alkaline earth metal cation, or a quaternary ammonium cation (or other quaternary nitrogen-containing cation).
  • these salts particularly preferred are the following selenites: sodium-selenite, potassium-selenite, magnesium-selenite and calcium-selenite, particularly preferred is the sodium-selenite.
  • the ratio of the active substances is given as mass ratio.
  • the mass ratios and mass percentage values in case of therapeutically acceptable salts of the listed active substances refer to the free bases/acids.
  • the mass ratio of the primary active substances can vary in a wide range, however it is typical, that the lipoic acid is present in a substantially higher amount than selenite.
  • the mass ratio of lipoic acid:selenite falls into the range of 10-10000: 1, preferably into the range of 50-5000: 1, more preferably into the range of 100- 3000: 1.
  • the group of secondary active substances does not include the conventionally applied high molecular weight chemotherapeutic compounds (such as e.g. cisplatin, doxorubicin, etoposide, paclitaxel, irinotecan HCL, vincristine).
  • the group of secondary active substances includes compounds with a maximal molecular weight of 280 daltons (the compounds are typically acids).
  • Preferred cases of such compounds are the following: L-tryptophan, D-tryptophan, L-methionine, D-phenylalanine, agmatine, phenylpyruvic acid, gentisic acid, pyrrole-2-carboxylic acid, L-arginine, D-arginine, L- phenylalanine, L-histidine, L-tyrosine, pyridoxine, D(+)-biotin, L(+)-ascorbic acid, L(-)-malic acid, D-(+)-glucosamine, ketoisocaproic acid (4-methyl-2-oxovaleric acid), cinnamic acid, adenosine, melatonin, p-coumaric acid and therapeutically acceptable salts of said compounds.
  • More preferred secondary active substances are the following: L-tryptophan, D- tryptophan, L-methionine, D-phenylalanine, agmatine, phenylpyruvic acid, gentisic acid, pyrrole-2-carboxylic acid and therapeutically acceptable salts of said compounds.
  • the secondary active substances are also typically applied in a high mass ratio compared to the selenite (if salts are applied then the calculation is also based on the free base/acid form of the substances).
  • the mass ratio of the "secondary active substance": selenite falls into the range of 10-10000: 1, preferably into the range of 50- 5000: 1, more preferably into the range of 100-3000: 1.
  • composition designates preferably a therapeutical composition, which may comprise usual therapeutically/pharmaceutically acceptable excipients (see in more detail below). However, the composition can also be formulated as a dietary supplement or foodstuff.
  • the active substances according to the invention and their therapeutically acceptable salts, and the therapeutical compositions made from them can be administered in any ordinary way. They can be used for example orally, parenterally (including subcutaneous, intramuscular and intravenous administration), buccally, sublingually, nasally, rectally or transdermally.
  • the therapeutical compositions are prepared in unit dosage form using the ordinary pharmaceutical procedures, the usual therapeutically/pharmaceutically acceptable carriers, diluents and/or other excipients.
  • the active substances according to the invention define the active substances according to the invention and/or therapeutically acceptable salts thereof.
  • compositions containing active substances according to the invention that are orally active can be prepared in a liquid or solid form.
  • active substances according to the invention that are orally active
  • syrup, suspension, emulsion, tablets, capsules or lozenges can be prepared.
  • the active substances according to the invention are prepared in liquid form, for example as a suspension solution, it will contain the active substances according to the invention in a suitable liquid carrier or carriers.
  • Aqueous solvents e.g. water, ethanol or glycerine
  • non-aqueous solvents e.g. polyethylene glycol or some sort of oil
  • the composition may also comprise suspending agents, preservatives, flavouring and colouring agents.
  • the solid composition is a tablet, it can be formulated with any suitable carrier routinely used in the preparation of medicaments.
  • Solid carriers can be for example lactose, suitable silicates, sucrose, talcum, gelatine, agar, pectin, gum arabic, magnesium stearate and stearic acid, etc.
  • a standard aqueous or non-aqueous coating can be applied on the tablets.
  • tablets can be prepared by pressing or moulding, optionally using one or more absorption promoting agents or adjuvants.
  • Tablets can be manufactured for example by means of a suitable tablet press machine; the active substance can be pressed in powder or granular form, optionally mixed with excipients, lubricants, inert diluents, surface active or dispersive agents.
  • the solid composition is a capsule, it can be manufactured using any ordinary encapsulation method.
  • pellets can be made from the active substances combined with a standard carrier, and then they can be filled in hard gelatine capsules.
  • a dispersion or suspension can be prepared from the active substances combined with a suitable pharmaceutical carrier, and then it can be filled in soft gelatine capsules.
  • suitable pharmaceutical carriers can be for example water-dispersible gums, cellulose, silicates or oils.
  • parenteral compositions are solutions or suspensions which contain the active substances according to the invention in sterile aqueous carriers or parentally administrable non-aqueous carriers, e.g. in polyethylene glycol, polyvinylpyrrolidone, lecithin, peanut oil or sesame oil.
  • sterile aqueous carriers or parentally administrable non-aqueous carriers e.g. in polyethylene glycol, polyvinylpyrrolidone, lecithin, peanut oil or sesame oil.
  • the solution can be lyophilized, and directly before administration it is transformed into a solution again with a suitable solvent.
  • compositions according to the invention suitable for nasal administration contain the active substances according to the invention in aerosols, drops, gel or powder form.
  • the aerosols according to the invention contain the active substances according to the invention typically in a solution or a finely dispersed suspension, in a physiologically acceptable aqueous or non-aqueous solvent.
  • the sterile aerosol can be packaged in a closed container containing a single dose or several doses, which container enables administration or refilling and is generally equipped with a nebuliser.
  • the closed container may also be suitable for the administration of unit doses; for example it can be an inhaler ensuring single doses, or an aerosol dispenser with a dispensing valve, which can be disposed of when the container is empty.
  • a propellant e.g. a compressed gas (e.g. compressed air) or an organic propellant (e.g. chlorinated/fluorinated hydrocarbons) can be used.
  • a nebuliser pump e.g. a nebuliser pump.
  • compositions according to the invention containing the active substances according to the invention are also suitable for buccal and sublingual administration, for example in the form of tablets, lozenges or pastilles; they contain the active substances formulated with a carrier (e.g. sugar and gum arabic, tragacanth, or gelatine, glycerine, etc.).
  • a carrier e.g. sugar and gum arabic, tragacanth, or gelatine, glycerine, etc.
  • composition containing the active substances according to the invention is also suitable for rectal administration.
  • suppositories are prepared, which contain the active substances in a suppository base such as cocoa butter or some other known carrier. Suppositories are prepared by usual method, by mixing the components, then softening and melting the mixture and pouring the melt into a mould and cooling it.
  • composition containing the active substances according to the invention is also suitable for transdermal administration, e.g. in the form of an ointment, gel or plaster.
  • the daily dose of the composition according to the invention is influenced by numerous factors such as the kind of the disease to be treated, the condition of the patient, the other ongoing treatments, the route of administration etc.
  • a composition comprising 5-500 mg, preferably 10-300 mg active substances per kg adult body weight, should be administered daily.
  • the daily dose should be administered in 1-15 portion(s) in the form of tablet, capsule, pill, drink powder, solution for infusion etc.
  • the suitable daily dose has been determined for mammals, specifically for humans.
  • the different types of cancer cells e.g. with different histological origin and type
  • the metabolism of which differ from the normal cells at different extent can show a various degree of sensitivity to combinations of the active substances according to the invention.
  • the qualitative and quantitative composition of the mixtures described in the present invention can be optimized for the given type of cancer by using the synergism as selection criterion.
  • the sensitivity of cancer cells isolated from the tumor tissue of a given individual to a composition according to the invention can also be determined, and the composition of the mixtures can be optimized (individualized therapy).
  • the composition according to the invention can be preferably used for the prevention and treatment of the following neoplastic disorders: malignant (cancerous) tumors, such as malignant neoplasms of lip, oral cavity and pharynx, malignant neoplasms of digestive organs, malignant neoplasms of respiratory and intrathoracic organs, malignant neoplasms of bone and articular cartilage, melanoma and other malignant neoplasms of skin, malignant neoplasms of mesothelial and soft tissue, malignant neoplasm of breast, malignant neoplasms of female genital organs, malignant neoplasms of male genital organs, malignant neoplasms of urinary tract, malignant neoplasms of eye, brain and other parts of central nervous system, malignant neoplasms of thyroid and other endocrine glands, malignant neoplasms of ill- defined, secondary and unspec
  • TELA American Type Culture Collection, product number: CCL-2
  • HELA American Type Culture Collection, product number: CCL-2
  • HELA High Efficiency Culture Collection
  • MEM media Sigma-Aldrich, product number: M2279
  • CI combination index
  • the value of the CI is between 0.85 and 0.90 then slight synergism; if the value of the CI is between 0.7 and 0.85 then moderate synergism; if the value of the CI is between 0.3 and 0.7 then synergism; if the value of the CI is between 0.1 and 0.3 then strong synergism; if the value of the CI ⁇ 0.1 then very strong synergism is present.
  • Dl and D2 are the doses of the two compounds in the D1+D2 combination which produce an inhibition of X%, while ⁇ and ⁇ 2 represents the doses of the two compounds which produce an inhibition of X% when the two compounds are applied per se. If the data points on the normalized isobologram are localized lower-left from the line connecting the ends of the two axes then synergism is present, if data points are localized along the connecting line then the effect of the two compounds is additive, and if data points are localized upper-right from the connecting line then antagonism is present.
  • the normalized isobologram shown in Figure 1 part "B" confirms that there is synergism in the antitumor effect between LA and sodium-selenite at the investigated concentrations.
  • TGI tumor growth
  • TGI values calculated on the basis of tumor volumes were the following: 25.8%, 34.4%, 23.3% on the 6 th , 8 th and 10 th days of the treatment, respectively.
  • the TGI calculated on the basis of tumor weight was 35.2%), p ⁇ 0.05 vs. control and vs. LA applied per se, p ⁇ 0.001 vs. sodium-selenite applied per se.
  • the result of the experiment provides in vivo confirmation of the in vitro demonstrated synergistic antitumor effect of LA and sodium-selenite.
  • Enantiomers of alpha-lipoic acid applied individually at 0.5 mM, 0.4 mM, 0.3 mM concentrations in combination with 1 ⁇ , 0.75 ⁇ , 0.5 ⁇ concentrations of sodium-selenite produce a synergistic antitumor effect on HELA cells.
  • synergistic antitumor activity seen upon the combined application of alpha-lipoic acid and sodium-selenite is not caused by reactive oxygen species formed from sodium-selenite in the cell culture media triggered by free SH-groups formed during the incidental reduction of alpha-lipoic acid, since if this would be the case we should have obtained a synergistic antitumor effect upon the combination of free SH-group containing compounds other than LA (reduced L-glutathione and L-cysteine) with sodium-selenite.
  • L-tryptophan synergistically enhances the antitumor effect of the mixture of ( ⁇ )-alpha-lipoic acid and sodium- selenite on HELA cells
  • D-tryptophan synergistically enhances the antitumor effect of the mixture of ( ⁇ )-alpha-lipoic acid and sodium- selenite on HELA cells
  • L-methionine synergistically enhances the antitumor effect of the mixture of ( ⁇ )-alpha-lipoic acid and sodium- selenite on HELA cells
  • D-phenylalanine synergistically enhances the antitumor effect of the mixture of ( ⁇ )-alpha-lipoic acid and sodium-selenite on HELA cells
  • Agmatine-sulfate synergistically enhances the antitumor effect of the mixture of ( ⁇ )-alpha-lipoic acid and sodium-selenite on HELA cells
  • sodium-phenylpyruvate synergistically enhances the antitumor effect of the mixture of LA and sodium-selenite, and the simultaneous presence of both LA and sodium-selenite is necessary for the occurrence of this synergism.
  • Pyrrole-2-carboxylic acid synergistically enhances the antitumor effect of the mixture of ( ⁇ )-alpha-lipoic acid and sodium-selenite on HELA cells
  • Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization, Biofactors 6 (1997) 321-338. [6] U.Wenzel, A. Nickel, H. Daniel, Alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant 02-*- generation, Apoptosis 10 (2005) 359-368.
  • Nonredox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo, J. Mol. Med. (Berl.) 89 (2011) 1137-1148.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'objet de l'invention est une composition synergique contenant exclusivement de l'acide lipoïque ou un sel thérapeutiquement acceptable dudit composé et de la sélénite en tant que substances actives primaires, facultativement en association avec une ou plusieurs substance(s) active(s) secondaire(s) avec un poids moléculaire maximal de 280 daltons, et facultativement en association avec un ou plusieurs support(s), diluant(s) et/ou autre(s) excipient(s) usuels thérapeutiquement acceptables.
PCT/HU2017/050013 2016-07-22 2017-05-03 Composition basée sur l'action synergique de l'acide lipoïque et de la sélénite et son utilisation pour la prévention et le traitement de troubles néoplasiques WO2018015776A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1600462 2016-07-22
HU1600462A HU231044B1 (hu) 2016-07-22 2016-07-22 Liponsav és szelenit szinergista hatásán alapuló készítmény és annak alkalmazása daganatos megbetegedések megelõzésében és kezelésében

Publications (1)

Publication Number Publication Date
WO2018015776A1 true WO2018015776A1 (fr) 2018-01-25

Family

ID=89992229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2017/050013 WO2018015776A1 (fr) 2016-07-22 2017-05-03 Composition basée sur l'action synergique de l'acide lipoïque et de la sélénite et son utilisation pour la prévention et le traitement de troubles néoplasiques

Country Status (2)

Country Link
HU (1) HU231044B1 (fr)
WO (1) WO2018015776A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041825A1 (fr) * 2019-08-30 2021-03-04 Musc Foundation For Research Development Composé du sélénium à base de sphingolipides, procédés de préparation associés et leurs utilisations pharmaceutiques, y compris en tant qu'agents antitumoraux

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086894A1 (en) 2000-10-06 2002-07-04 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
WO2004107881A1 (fr) * 2003-06-04 2004-12-16 Serfontein, Willem, Jacob Compositions nutritives, et utilisation
WO2005048925A2 (fr) * 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Procedes de traitement d'une maladie neoplasique chez un sujet au moyen de composes de selenium inorganique
US20110008418A1 (en) 2006-02-16 2011-01-13 Young Hee Ko Compositions and Methods for the Treatment of Cancer
EP2296643A1 (fr) 2008-06-23 2011-03-23 N.V. Nutricia Composition nutritionnelle pour améliorer le système immunitaire des mammifères
WO2013156971A1 (fr) * 2012-04-20 2013-10-24 Giellepi S.P.A Composition comprenant de l'acide alpha-lipoïque et de l'honokiol pour le traitement de neuropathies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086894A1 (en) 2000-10-06 2002-07-04 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
WO2004107881A1 (fr) * 2003-06-04 2004-12-16 Serfontein, Willem, Jacob Compositions nutritives, et utilisation
WO2005048925A2 (fr) * 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Procedes de traitement d'une maladie neoplasique chez un sujet au moyen de composes de selenium inorganique
US20110008418A1 (en) 2006-02-16 2011-01-13 Young Hee Ko Compositions and Methods for the Treatment of Cancer
EP2296643A1 (fr) 2008-06-23 2011-03-23 N.V. Nutricia Composition nutritionnelle pour améliorer le système immunitaire des mammifères
WO2013156971A1 (fr) * 2012-04-20 2013-10-24 Giellepi S.P.A Composition comprenant de l'acide alpha-lipoïque et de l'honokiol pour le traitement de neuropathies

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
"Handbook of Statistics, Analysis of Variance", vol. 1, 1980, pages: 1 - 1002
A. GODER; G. NAGEL; A. KRAUS; B. DORSAM; N. SEIWERT; B. KAINA ET AL.: "Lipoic acid inhibits the DNA repair protein O-6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction", CARCINOGENESIS, vol. 36, 2015, pages 817 - 831
B. DORSAM; A. GODER; N. SEIWERT; B. KAINA; J. FAHRER: "Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil", ARCH. TOXICOL., vol. 89, 2015, pages 1829 - 1846, XP035547745, DOI: doi:10.1007/s00204-014-1434-0
B. FEUERECKER; S. PIRSIG; C. SEIDL; M. AICHLER; A. FEUCHTINGER; G. BRUCHELT ET AL.: "Lipoic acid inhibits : cell proliferation of tumor cells in vitro and in vivo", CANCER BIOL. THER., vol. 13, 2012, pages 1425 - 1435
C.K. SEN; R. SASHWATI; L. PACKER: "Fas mediated apoptosis of human Jurkat T-cells: intracellular events and potentiation by redox-active alpha-lipoic acid", CELL DEATH DIFFER., vol. 6, 1999, pages 481 - 491
D. HAN; G. HANDELMAN; L. MARCOCCI; C.K. SEN; S. ROY; H. KOBUCHI ET AL.: "Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization", BIOFACTORS, vol. 6, 1997, pages 321 - 338
G.R. HAENEN; A. BAST: "Scavenging of hypochlorous acid by lipoic acid", BIOCHEM. PHARMACOL., vol. 42, 1991, pages 2244 - 2246, XP023730073, DOI: doi:10.1016/0006-2952(91)90363-A
H. LUO; Y. YANG; F. HUANG; F. LI; Q. JIANG; K. SHI ET AL.: "Selenite induces apoptosis in colorectal cancer cells via akt-mediated inhibition of β-catenin survival axis", CANCER LETT., vol. 315, 2012, pages 78 - 85, XP028599281, DOI: doi:10.1016/j.canlet.2011.10.014
H. SIGEL; B. PRIJS; D.B. MCCORMICK; J.C. SHIH: "Stability and structure of binary and ternary complexes of alpha-lipoate and lipoate derivatives with Mn2+, Cu2+, and Zn2+ in solution", ARCH. BIOCHEM. BIOPHYS, vol. 187, 1978, pages 208 - 214, XP024806686, DOI: doi:10.1016/0003-9861(78)90025-5
J. CHAUDIERE; O. COURTIN; J. LECLAIRE: "Glutathione oxidase activity of selenocystamine: A mechanistic study", ARCH. BIOCHEM. BIOPHYS, vol. 296, 1992, pages 328 - 336, XP024815773, DOI: doi:10.1016/0003-9861(92)90580-P
J. MOUNGJAROEN; U. NIRHMANNIT; P.S. CALLERY; L.WANG; N. AZAD; V. LIPIPUN ET AL.: "Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation", J. PHARMACOL. EXP. THER., vol. 319, 2006, pages 1062 - 1069
J.E. SPALLHOLZ; B.J. SHRIVER; T.W. REID: "Dimethyldiselenide and methylseleninic acid generate superoxide in an in vitro chemiluminescence assay in the presence of glutathione: Implications for the anticarcinogenic activity of L-selenomethionine and L-se-methylselenocysteine. Nutr", CANCER, vol. 40, 2001, pages 34 - 41
K. VAN DE MARK; J.S. CHEN; K. STELIOU; S.P. PERRINE; D.V. FALLER: "Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines", J. CELL.PHYSIOI., vol. 194, 2003, pages 325 - 340, XP008037152, DOI: doi:10.1002/jcp.10205
KULCSÁR G ET AL: "A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 132, no. 5, 1 March 2013 (2013-03-01), pages 1213 - 1221, XP002745253, ISSN: 0020-7136, [retrieved on 20120824], DOI: 10.1002/IJC.27756 *
L. ROCHETTE; S. GHIBU; C. RICHARD; M. ZELLER; Y. COTTIN; C. VERGELY: "Direct and indirect antioxidant properties of alpha-lipoic acid and therapeutic potential", MOL. NUTR. FOOD RES., vol. 57, 2013, pages 114 - 125
L.V. PAPP; J. LU; A. HOLMGREN; K.K. KHANNA: "From selenium to selenoproteins: synthesis, identity, and their role in human health", ANTIOXID REDOX SIGNAL, vol. 9, 2007, pages 775 - 806, XP055280560, DOI: doi:10.1089/ars.2007.1528
M. ABOLHASSANI; A. GUAIS; E. SANDERS; F. CAMPION; I. FICHTNER; J. BONTE ET AL.: "Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice", INVEST. NEW DRUGS, vol. 30, 2012, pages 1331 - 1342, XP035079557, DOI: doi:10.1007/s10637-011-9692-7
M. WALLENBERG; S. MISRA; A.M. WASIK; C. MARZANO; M. BJORNSTEDT; V. GANDIN ET AL.: "Selenium induces a multi-targeted cell death process in addition to ros formation", J. CELL MOL. MED., vol. 18, 2014, pages 671 - 684
MARK VAN DE K ET AL: "ALPHA-LIPOIC ACID INDUCES P27KIP-DEPENDENT CELL CYCLE ARREST IN NON-TRANSFORMED CELL LINES AND APOPTOSIS IN TUMOR CELL LINES", JOURNAL OF CELLULAR PHYSIO, WILEY SUBSCRIPTION SERVICES, INC, US, vol. 194, no. 3, 1 March 2003 (2003-03-01), pages 325 - 340, XP008037152, ISSN: 0021-9541, DOI: 10.1002/JCP.10205 *
O. BRODIN; S. EKSBORG; M. WALLENBERG; C. ASKER-HAGELBERG; E.H. LARSEN; D. MOHLKERT ET AL.: "Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study", NUTRIENTS, vol. 7, 2015, pages 4978 - 4994, XP055257918, DOI: doi:10.3390/nu7064978
P. KAFARA; P. ICARD; M. GUILLAMIN; L. SCHWARTZ; H. LINCET: "Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death", J. OVARIAN RES., vol. 8, 2015, pages 36
P.B. CAFFREY; G.D. FRENKEL: "Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite", ANTICANCER RES., vol. 10, 2013, pages 4249 - 4254
P.B. CAFFREY; G.D. FRENKEL: "Selenite enhances and prolongs the efficacy of cisplatin treatment of human ovarian tumor xenografts", IN VIVO, vol. 26, 2012, pages 549 - 552
P.B. CAFFREY; G.D. FRENKEL: "Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance", ANTICANCER RES., vol. 18, 1998, pages 3017 - 3020, XP008041651
P.B. CAFFTEY; G.D. FRENKEL: "Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo", CANCER CHEMOTHER PHARMACOL., vol. 46, 2000, pages 74 - 78
Q. JIANG; Y. WANG; T. LI; K. SHI; Z. LI; Y. MA ET AL.: "Heat shock protein 90-mediated inactivation of nuclear factor- b switches autophagy to apoptosis through becnl transcriptional inhibition ,in selenite-induced nb4 cells", MOL. BIOL. CELL, vol. 22, 2011, pages 1167 - 1180
R.A. PACK; K. HARDY; M.C. MADIGAN; N.H. HUNT: "Differential effects of the antioxidant alpha-lipoic acid on the proliferation of mitogen-stimulated peripheral blood lymphocytes and leukaemic T cells", MOL. IMMUNOL., vol. 38, 2002, pages 733 - 745
S. KUMAR; M. BJORNSTEDT; A. HOLMGREN: "Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen", EUR. J. BIOCHEM., vol. 207, 1992, pages 435 - 439
S. MISRA; M. BOYLAN; A. SELVAM; J.E. SPALLHOLZ; M. BJÖRNSTEDT: "Redox-active selenium compounds-from toxicity and cell death to cancer treatment", NUTRIENTS, vol. 7, 2015, pages 3536 - 3556
S.J. ZHANG; Q.F. GE; D.W. GUO; W.X. HU; H.Z. LIU: "Synthesis and anticancer evaluation of alpha-lipoic acid derivatives", BIOORG. MED. CHEM. LETT., vol. 20, 2010, pages 3078 - 3083
T. HIRATSUKA; M. INOMATA; Y. KONO; S. YOKOYAMA; N. SHIRAISHI; S. KITANO: "DHLTauZnNa, a newly synthesized alpha-lipoic acid derivative, induces autophagy in human colorectal cancer cells", ONCOL. REP., vol. 29, 2013, pages 2140 - 2146
T.C CHOU: "Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies", PHARMACOL REV, vol. 58, 2006, pages 621 - 681, XP055151376, DOI: doi:10.1124/pr.58.3.10
T.C CHOU; P. TALALAY: "Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors", EUR J BIOCHEM., vol. 115, 1981, pages 207 - 216
T.C CHOU; P. TALALAY: "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors", ADV ENZYME REGUL, vol. 22, 1984, pages 27 - 55, XP023796270, DOI: doi:10.1016/0065-2571(84)90007-4
T.H. YOO; J.H. LEE; H.S. CHUN; S.G. CHI: "Alpha-Lipoic acid prevents p53 degradation in colon cancer cells by blocking NF-kappaB induction of RPS6KA4", ANTICANCER DRUGS, vol. 24, 2013, pages 555 - 565
T.S. PARDEE; K. LEE; J. LUDDY; C. MATURO; R. RODRIGUEZ; S. ISOM ET AL.: "A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies", CLIN. CANCER RES., vol. 20, 2014, pages 5255 - 5264
U.WENZEL; A. NICKEL; H. DANIEL: "Alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant 02-*-generation", APOPTOSIS, vol. 10, 2005, pages 359 - 368, XP019204679, DOI: doi:10.1007/s10495-005-0810-x
Y.J. SUZUKI; M. TSUCHIYA; L. PACKER: "Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species", FREE RADIC. RES.COMMUN., vol. 15, 1991, pages 255 - 263, XP000608027
Z. ZACHAR; J. MARECEK; C. MATURO; S. GUPTA; S.D. STUART; K. HOWELL ET AL.: "Nonredox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo", J. MOL. MED. (BERL., vol. 89, 2011, pages 1137 - 1148, XP019965329, DOI: doi:10.1007/s00109-011-0785-8

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041825A1 (fr) * 2019-08-30 2021-03-04 Musc Foundation For Research Development Composé du sélénium à base de sphingolipides, procédés de préparation associés et leurs utilisations pharmaceutiques, y compris en tant qu'agents antitumoraux

Also Published As

Publication number Publication date
HU231044B1 (hu) 2020-01-28
HUP1600462A2 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
Gandin et al. Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment
Dörsam et al. The disulfide compound α-lipoic acid and its derivatives: a novel class of anticancer agents targeting mitochondria
Omar et al. Organosulfur compounds and possible mechanism of garlic in cancer
Nair et al. Saffron chemoprevention in biology and medicine: a review
Wouters et al. Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
Perrone et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo
FI119100B (fi) Flavanolignaanien käyttö valmistettaessa lääkkeitä, joilla on antiproliferatiivista vaikutusta kohdussa, munasarjoissa ja rintarauhasessa
JP3953513B2 (ja) ピペリン含有組成物
Keating et al. Antimetabolic effects of polyphenols in breast cancer cells: Focus on glucose uptake and metabolism
Novotny et al. Alpha-lipoic acid-the potential for use in cancer therapy minireview
US20130295068A1 (en) Combination preparation for improving sperm quality
TW201204267A (en) Compositions and beverages comprising nutrients, vitamins, sugars, cysteine, and/or sugar-cysteine products
AU2013202507B9 (en) Inhibition of drug resistant cancer cells
KR102375288B1 (ko) 대사항암제를 포함하는 항암용 조성물
May Selenium-based drug design: rationale and therapeutic potential
EP1123097B1 (fr) Composition pharmaceutique contenant de la decursine
WO2018015776A1 (fr) Composition basée sur l'action synergique de l'acide lipoïque et de la sélénite et son utilisation pour la prévention et le traitement de troubles néoplasiques
Suski et al. Mitochondrial tolerance to drugs and toxic agents in ageing and disease
US20090264421A1 (en) Methods and Compositions for Treating Cancer
TW202135801A (zh) 含有芝麻素類及吡咯喹啉醌（ｐｑｑ）之組成物
WO2012075754A1 (fr) Composition pharmaceutique servant à traiter la leucémie lymphoïde aiguë
Shilpi et al. Vitamin-C: properties, function and application in cancer therapy
Bordignon et al. Ascorbic acid derivatives as a new class of antiproliferative molecules
WO2014116097A2 (fr) Compositions pour le traitement systémique d'affections pathologiques résultant du stress oxydatif et/ou du déséquilibre redox
WO2008007367A1 (fr) Thérapies combinées pour le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17729912

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17729912

Country of ref document: EP

Kind code of ref document: A1